Tran Elizabeth, Spiceland Clayton, Sandhu Nicole P, Jatoi Aminah
Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Department of Oncology, Mayo Clinic, Rochester, MN, USA
Am J Hosp Palliat Care. 2016 Apr;33(3):272-5. doi: 10.1177/1049909114566225. Epub 2014 Dec 31.
We sought to report incidence, risk factors, and survival related to bowel obstruction in 311 ovarian cancer patients with recurrent disease. A total of 68 (22%) had a documented bowel obstruction during their cancer course, and 49 (16%) developed it after cancer recurrence. Surprisingly, 142 (45%) fit into an "unknown" category (3+ months of data lacking from last contact/death). No risk factors were identified; management included surgery (n = 21), conservative measures (n = 21), and other (n = 7). Documented bowel obstruction was not associated with a statistically significant reduction in survival after cancer recurrence. In conclusion, although bowel obstruction occurs in only a subgroup of patients with ovarian cancer and does not appear to detract from survival after cancer recurrence, limited end-of-life information may be resulting in an underestimation of incidence.
我们试图报告311例复发性卵巢癌患者肠梗阻的发病率、危险因素及生存率。共有68例(22%)患者在癌症病程中记录有肠梗阻,49例(16%)在癌症复发后出现肠梗阻。令人惊讶的是,142例(45%)属于“未知”类别(自上次接触/死亡起缺乏3个月以上的数据)。未发现危险因素;治疗措施包括手术(n = 21)、保守治疗(n = 21)及其他(n = 7)。记录的肠梗阻与癌症复发后的生存率在统计学上无显著降低相关。总之,虽然肠梗阻仅发生在部分卵巢癌患者中,且似乎并不影响癌症复发后的生存率,但有限的临终信息可能导致发病率被低估。